See more : Airtel Africa Plc (AARTY) Income Statement Analysis – Financial Results
Complete financial analysis of Histogen Inc. (HSTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Histogen Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Seed Capital Solutions Plc (SCSP.L) Income Statement Analysis – Financial Results
- Canadian Net Real Estate Investment Trust (CNNRF) Income Statement Analysis – Financial Results
- Renishaw plc (RSW.L) Income Statement Analysis – Financial Results
- Kaival Brands Innovations Group, Inc. (KAVL) Income Statement Analysis – Financial Results
- SDIC Zhonglu Fruit Juice Co.,Ltd. (600962.SS) Income Statement Analysis – Financial Results
Histogen Inc. (HSTO)
About Histogen Inc.
Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.77M | 919.00K | 2.06M | 11.30M | 33.59M | 35.38M | 799.05K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 220.00K | 968.00K | 2.22M | 0.00 | -4.00 | -4.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 3.77M | 699.00K | 1.09M | 9.09M | 33.59M | 35.38M | 799.05K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 76.06% | 52.99% | 80.41% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 5.02M | 8.47M | 6.22M | 4.10M | 41.37M | 43.22M | 20.29M | 16.30M | 14.91M | 6.95M |
| General & Administrative | 9.39M | 7.80M | 6.59M | 6.21M | 10.50M | 9.71M | 10.34M | 7.83M | 7.38M | 4.65M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -91.00K | -108.30K | -105.84K | 0.00 | 0.00 | 0.00 |
| SG&A | 9.39M | 7.80M | 6.59M | 6.21M | 10.40M | 9.60M | 10.23M | 7.83M | 7.38M | 4.65M |
| Other Expenses | 0.00 | -113.00K | 105.00K | -150.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.41M | 16.16M | 12.81M | 10.16M | 51.77M | 52.82M | 30.52M | 24.13M | 22.29M | 11.60M |
| Cost & Expenses | 14.41M | 16.38M | 13.77M | 12.37M | 51.86M | 52.93M | 30.63M | 24.13M | 22.29M | 11.60M |
| Interest Income | 0.00 | 0.00 | 0.00 | 568.00K | 962.00K | 892.18K | 138.41K | 67.89K | 0.00 | 0.00 |
| Interest Expense | 1.00K | 10.00K | 64.00K | 0.00 | 696.00K | 662.40K | 70.00K | 70.00K | 70.00K | 462.57K |
| Depreciation & Amortization | 140.00K | 97.00K | 98.00K | 145.00K | 91.00K | 108.30K | 105.84K | 67.86K | -538.90K | 10.45K |
| EBITDA | -10.50M | -14.90M | -18.66M | -2.86M | -17.22M | -16.63M | -29.56M | -24.01M | -22.79M | -15.14M |
| EBITDA Ratio | -278.67% | -1,680.85% | -221.95% | 9.29% | -54.15% | -49.30% | -3,720.18% | 0.00% | 0.00% | 0.00% |
| Operating Income | -10.64M | -15.46M | -11.71M | 905.00K | -18.28M | -17.55M | -29.83M | -24.15M | -22.32M | -15.62M |
| Operating Income Ratio | -282.38% | -1,681.94% | -568.92% | 8.01% | -54.42% | -49.61% | -3,733.42% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -1.00K | 448.00K | -7.10M | -1.93M | 267.00K | 154.07K | 98.33K | -17.92K | 0.00 | -4.02M |
| Income Before Tax | -10.64M | -15.01M | -18.82M | -3.00M | -18.01M | -17.40M | -29.73M | -24.15M | -22.32M | -15.62M |
| Income Before Tax Ratio | -282.41% | -1,633.19% | -913.89% | -26.55% | -53.62% | -49.17% | -3,721.12% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -604.00K | 6.96M | 1.90M | 963.00K | 816.47K | 168.32K | 70.00K | 70.00K | 462.57K |
| Net Income | -10.62M | -14.41M | -25.77M | -4.90M | -18.01M | -17.40M | -29.73M | -24.15M | -22.32M | -15.62M |
| Net Income Ratio | -281.80% | -1,567.46% | -1,251.77% | -43.33% | -53.62% | -49.17% | -3,721.12% | 0.00% | 0.00% | 0.00% |
| EPS | -3.46 | -7.51 | -57.16 | -8.29 | -118.60 | -121.71 | -262.55 | -1.30 | -1.44 | -2.12 |
| EPS Diluted | -3.46 | -7.51 | -57.16 | -8.29 | -118.60 | -121.71 | -262.55 | -1.30 | -1.44 | -2.12 |
| Weighted Avg Shares Out | 3.21M | 1.92M | 450.92K | 590.69K | 151.85K | 142.93K | 113.25K | 18.62M | 15.48M | 7.36M |
| Weighted Avg Shares Out (Dil) | 3.21M | 1.92M | 450.92K | 590.69K | 151.85K | 142.93K | 113.25K | 18.62M | 15.48M | 7.36M |
Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering
SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the “Company” or “Histogen”), a drug development company for treatment of bacterial skin infections, today announced that it has filed voluntary petitions for relief under subchapter V of Chapter...
Histogen Announces Second Adjournment of Special Meeting of Stockholders
Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PT Potential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved
Histogen Announces Adjournment of Special Meeting of Stockholders
SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC: HSTO) today announced that its special meeting of stockholders (the “Special Meeting”) has been adjourned to Thursday, December 14, 2023 at 8:00 a.m. Pacific Time with respect to both...
Histogen Announces Board Approval of Complete Liquidation and Dissolution
SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved and adopted a Plan of Dissolution (“Plan of Dissolution”) that would include...
Top Sectors to Explore for Penny Stocks to Buy
Are you buying penny stocks in these sectors? The post Top Sectors to Explore for Penny Stocks to Buy appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny Stock Psychology: Developing a Winning Mindset
Use these tips for having a winning penny stocks trading mindset The post Penny Stock Psychology: Developing a Winning Mindset appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Why Is Histogen (HSTO) Stock Up 37% Today?
Histogen (NASDAQ: HSTO ) stock is rising higher on Friday after getting a patent for CTS-2090. The patent is titled “Caspase Inhibitors and Methods of Use Thereof.
Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration
MCLEAN, Va.--(BUSINESS WIRE)--Amerimmune LLC is a translational medicine biotechnology firm focused on discovery and rapid development of novel therapies for diseases, including COVID-19. Amerimmune LLC had a discovery early in 2020, showing elevated caspase molecules in peripheral blood immune cells...
Histogen (HSTO) Upgraded to Strong Buy: Here's What You Should Know
Histogen (HSTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Buying Biotech Penny Stocks? 3 Things to Look For
Are biotech penny stocks on your buy list right now The post Buying Biotech Penny Stocks? 3 Things to Look For appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Source: https://incomestatements.info
Category: Stock Reports